U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H17NO3
Molecular Weight 295.3325
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDOBUFEN

SMILES

CCC(C(O)=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O

InChI

InChIKey=AYDXAULLCROVIT-UHFFFAOYSA-N
InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula C18H17NO3
Molecular Weight 295.3325
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis. Indobufen under brand name ibustrin is used in Italy for the following conditions: cerebrovascular insufficiency, atherosclerosis of peripheral and cerebral vessels, thrombophlebitis, deep vein thrombosis, and diabetes mellitus. In addition, this drug has been investigated in the phase II clinical trial for the prevention of thromboembolic events in patients with nonrheumatic atrial fibrillation. After oral administration, it is quickly and completely absorbed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions
PubMed

PubMed

TitleDatePubMed
Resolution of indobufen enantiomers by capillary zone electrophoresis. Pharmacokinetic studies of human serum.
2004 Apr 2
Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack.
2004 Oct 18
[Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma].
2005 Aug
Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism.
2006 Jan
Antithrombotic therapy in cardiac embolism.
2010 Aug

Sample Use Guides

indobufen capsules 100 and 200 mg
Route of Administration: Oral
In Vitro Use Guide
At low concentrations (10 microM), indobufen completely inhibited secondary platelet aggregation, the release reaction and TxB2 production stimulated by ADP, epinephrine and low concentrations of platelet-activating factor (PAF acether). Higher concentrations of indobufen (100 microM) completely inhibited TxB2 production, platelet aggregation and ATP release induced by arachidonic acid (1 mM) or collagen (2 micrograms/ml). The inhibitory effect was partially overcome by higher concentrations of arachidonic acid (2 mM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:21 UTC 2023
Edited
by admin
on Fri Dec 15 15:42:21 UTC 2023
Record UNII
6T9949G4LZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDOBUFEN
INN   MART.   MI   WHO-DD  
INN  
Official Name English
2-(4-(1-CARBOXYPROPYL)PHENYL)-1-ISOINDOLINONE
Systematic Name English
K-2930
Code English
Indobufen [WHO-DD]
Common Name English
BENZENEACETIC ACID, 4-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-.ALPHA.-ETHYL-, (±)-
Systematic Name English
INDOBUFEN [MI]
Common Name English
indobufen [INN]
Common Name English
IBUSTRIN
Brand Name English
(±)-2-(P-(1-OXO-2-ISOINDOLINYL)PHENYL)BUTYRIC ACID
Common Name English
INDOBUFEN [MART.]
Common Name English
K-3920
Code English
4-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-.ALPHA.-ETHYLBENZENEACETIC ACID
Systematic Name English
BENZENEACETIC ACID, 4-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-.ALPHA.-ETHYL-
Common Name English
1-OXO-2-(P-((.ALPHA.-ETHYL)CARBOXYMETHYL)PHENYL)ISOINDOLINE
Common Name English
Classification Tree Code System Code
WHO-ATC B01AC10
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
WHO-VATC QB01AC10
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
NCI_THESAURUS C257
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
Code System Code Type Description
DRUG BANK
DB12545
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
MERCK INDEX
m6271
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C83800
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
SMS_ID
100000088261
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
CAS
36690-96-7
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
SUPERSEDED
FDA UNII
6T9949G4LZ
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
MESH
C020371
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
EPA CompTox
DTXSID7057789
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
WIKIPEDIA
INDOBUFEN
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
PUBCHEM
107641
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
ChEMBL
CHEMBL1765292
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
DRUG CENTRAL
1439
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
RXCUI
27518
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY RxNorm
CAS
63610-08-2
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
INN
4398
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
EVMPD
SUB08176MIG
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
ECHA (EC/EINECS)
264-364-4
Created by admin on Fri Dec 15 15:42:21 UTC 2023 , Edited by admin on Fri Dec 15 15:42:21 UTC 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY